Inclusion Criteria:

          -  (Monotherapy - Parts A, B, C, D, G, H, J, and K) -- Histologically confirmed advanced
             malignancy, either: (a) Metastatic or unresectable solid malignancy; or (b) Classical
             Hodgkin lymphoma (HL), or diffuse large B-cell lymphoma (DLBCL), or indolent lymphoma
             (including follicular lymphoma [FL])

          -  (Monotherapy - Parts A, B, C, D, G, H, J, and K) -- Relapsed, refractory, or
             progressive disease, specifically: (a) Solid tumors: Following at least 1 prior
             systemic therapy, and no further standard therapy is available for the patient's
             advanced solid tumor at the time of enrollment; or (b) Classical HL: Following at
             least 2 prior systemic therapies in patients who are not candidates for autologous
             stem cell transplant (SCT), or following failure of autologous SCT; or (c) DLBCL:
             Following at least 1 prior systemic therapy; patients must have also received
             intensive salvage therapy unless they refused or were deemed ineligible; or (d)
             Indolent lymphoma: Following at least 1 prior chemoimmunotherapy regimen that included
             an anti-CD20 monoclonal antibody and for which no other more appropriate treatment
             option exists

          -  (Combination Therapy - Part E and Part F) -- Histologically or cytologically confirmed
             advanced or metastatic solid malignancy for which pembrolizumab treatment is approved.
             In Part F, other advanced solid tumor indications may be eligible as identified by the
             Sponsor.

          -  (Pancreatic Cancer Cohort - Part L) - Histologically or cytologically confirmed
             metastatic exocrine ductal adenocarcinoma of the pancreas not amenable to curative
             therapy. Patients must not have received any prior systemic therapy for metastatic
             disease; patients who have received prior therapy for non-metastatic pancreatic
             adenocarcinoma are eligible if therapy was fully completed more than 4 months before
             start of study treatment.

          -  Representative baseline tumor tissue sample is available (Parts A-K)

          -  Measurable disease

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

          -  Adequate baseline hematologic, renal, and hepatic function

          -  Recovery to Grade 1 of any clinically significant toxicity attributed to prior
             anticancer therapy prior to initiation of study drug administration

        Exclusion Criteria:

          -  Parts A-K

               1. Prior chemotherapy, small molecule inhibitors, and/or other investigational
                  anticancer agents (excluding investigational monoclonal antibodies) within 4
                  weeks

               2. Prior radiotherapy: therapeutic radiotherapy within 4 weeks, or palliative
                  radiotherapy (to non-CNS disease) within 1 week

               3. Prior immune-checkpoint inhibitors within 4 weeks (or 8 weeks, if immuno-oncology
                  doublet used as the prior line of therapy)

               4. Prior monoclonal antibodies, antibody-drug conjugates, or radioimmunoconjugates
                  within 4 weeks (or 2 weeks if patient experienced disease progression on the
                  prior treatment)

               5. Prior T-cell or other cell-based therapies within 12 weeks (or 2 weeks if patient
                  experienced disease progression on the prior treatment)

          -  Part L

               1. History of radiation pneumonitis

               2. Neuropathy Grade 2 or higher

               3. Has received prior therapy with an anti-PD-1, anti-PDL1, or anti-PD-L2 agent,
                  with an agent directed to another stimulatory or co-inhibitory T-cell receptor

               4. Has had allogenic tissue/solid organ transplant

          -  All Parts

               1. Recent or ongoing serious infections within 2 weeks

               2. Known positivity for hepatitis B infection

               3. Known active hepatitis C infection

               4. Active autoimmune or auto-inflammatory ocular disease within 6 months

               5. Known or suspected active organ-threatening autoimmune disease

               6. Active central nervous system tumor or metastases

          -  Patients with lymphomas: prior allogeneic SCT

          -  Patients in Part E, F, or L: history of severe immune-mediated adverse reactions or
             severe hypersensitivity to pembrolizumab